Oragenics Receives Going Concern Qualification in Annual Audit

Oragenics Inc. (NYSE American: OGEN) has reported that its audited financial statements for the year ended December 31, 2025, included an unqualified audit opinion accompanied by an explanatory paragraph regarding the company's ability to continue as a going concern. This disclosure was made in accordance with NYSE American requirements and was included in the company's Form 10-K filed on March 16, 2026. The announcement clarifies that this disclosure does not reflect any changes to the company's financial statements or its previously filed annual report. The going concern qualification is a significant accounting matter that indicates substantial doubt exists about a company's ability to continue operating for the foreseeable future, typically defined as the next twelve months.

The implications of this disclosure are substantial for Oragenics, a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. The company is advancing its lead candidate, ONP-002, as a potential first-in-class treatment for concussion and mild traumatic brain injury. Oragenics is working on commencing clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. The company's intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. A going concern qualification raises questions about the company's financial resources to continue funding these critical research and development activities, which are essential for bringing innovative therapies to market.

For investors and stakeholders, this disclosure represents a critical risk factor that must be considered when evaluating the company's prospects. The going concern qualification suggests that Oragenics may face challenges in securing sufficient capital to sustain operations through the lengthy and expensive clinical trial process required for drug development. Biotechnology companies typically require substantial funding to advance through clinical trial phases, and financial instability can jeopardize research timelines and regulatory approval pathways. The company's commitment to developing innovative therapies that address significant unmet medical needs in neurological care now faces the additional hurdle of demonstrating financial viability to regulators, partners, and the investment community.

The announcement was made through standard regulatory channels, and investors seeking additional information can access the company's newsroom at https://ibn.fm/OGEN. The disclosure follows established accounting standards that require auditors to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern. When such doubt exists, auditors must include an explanatory paragraph in their audit opinion, even when the financial statements themselves are presented fairly in accordance with accounting principles. This creates a distinction between the accuracy of the financial reporting and the underlying financial health of the company, with the going concern qualification specifically addressing the latter concern.

For the biotechnology sector, going concern qualifications are not uncommon among clinical-stage companies that have not yet generated revenue from product sales and rely heavily on investor funding. However, they serve as important markers of financial stress that can influence investment decisions, partnership negotiations, and strategic planning. Oragenics' disclosure comes at a pivotal time as the company prepares for important clinical milestones with ONP-002. The company's ability to address the concerns raised in the audit opinion will likely depend on successful capital raising, strategic partnerships, or demonstration of compelling clinical data that attracts additional investment. The intersection of scientific promise and financial sustainability remains a central challenge for many biotechnology companies navigating the path from research to commercialization.